Enanta Pharmaceuticals Inc income statement

In fiscal 2025, Enanta Pharmaceuticals Inc reported revenue of $65.3m, down 3.4% on the year before, operating income of −$85.3m (a -130.7% margin) and net income of −$81.9m, or −$3.84 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Enanta Pharmaceuticals Inc: income statement, annual
Fiscal year	2011Sept 2011	2012Sept 2012	2013Sept 2013	2014Sept 2014	2015Sept 2015	2016Sept 2016	2017Sept 2017	2018Sept 2018	2019Sept 2019	2020Sept 2020	2021Sept 2021	2022Sept 2022	2023Sept 2023	2024Sept 2024	2025Sept 2025	LTMJun 2026
Revenue	42	42	32	48	161	88	103	207	205	122	97	86	79	68	65	65
Research and development	12	15	17	19	23	40	57	95	142	137	174	165	164	131	107	86
General and administrative	5	5	6	10	14	17	21	23	26	27	33	45	53	58	44	38
Operating income	25	21	9	19	124	31	25	88	37	−42	−110	−124	−137	−122	−85	−59
Interest expense	3	—	0	0	0	0	0	—	—	—	0	0	5	11	8	13
Income before tax	—	21	10	19	125	33	27	93	46	−35	−108	−122	−131	−118	−84	−63
Income tax	0	0	0	−15	46	11	9	21	−1	1	−29	−0	3	−2	−2	0
Net income	23	21	10	34	79	22	18	72	46	−36	−79	−122	−134	−116	−82	−63
Diluted EPS	$0.17	$0.14	−$0.34	$1.80	$4.09	$1.13	$0.91	$3.48	$2.21	−$1.81	−$3.92	−$5.91	−$6.38	−$5.48	−$3.84	—
Diluted shares (average)	15m	20m	20m	19m	19m	19m	19m	21m	21m	20m	20m	21m	21m	21m	21m	—
EBITDA	26	21	9	19	125	33	27	91	40	−38	−106	−121	−135	−119	−81	−54

US$ millions unless shown otherwise. Fiscal quarters.

Enanta Pharmaceuticals Inc: income statement, quarterly
Quarter	2024 Q4Sept 2024	2025 Q1Dec 2024	2025 Q2Mar 2025	2025 Q3Jun 2025	2025 Q4Sept 2025	2026 Q1Dec 2025	2026 Q2Mar 2026	2026 Q3Jun 2026
Revenue	15	17	15	18	15	19	17	14
Research and development	31	28	28	27	24	21	19	22
General and administrative	14	13	11	10	10	9	10	9
Operating income	−30	−24	−25	−19	−18	−11	−12	−17
Interest expense	3	2	2	2	2	3	3	4
Income before tax	−29	−23	−24	−18	−19	−12	−13	−19
Income tax	−0	−0	−1	0	0	0	0	0
Net income	−29	−22	−23	−18	−19	−12	−13	−20
Diluted EPS	−$1.36	−$1.05	−$1.06	−$0.85	−$0.88	−$0.42	−$0.45	−$0.67
EBITDA	−29	−23	−23	−18	−17	−10	−11	−16

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ABCL vs ENTA CUVL vs ENTA CYTK vs ENTA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Enanta Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Enanta Pharmaceuticals Inc.